Reuters logo
BRIEF-Ablynx expects Phase II results of rare blood disorder study in first half of 2014
January 13, 2014 / 6:50 AM / in 4 years

BRIEF-Ablynx expects Phase II results of rare blood disorder study in first half of 2014

BRUSSELS, Jan 13 (Reuters) - Ablynx NV : * Phaseii data on anti-vWF Nanobody, Caplacizumab,to treat acquired thrombotic thrombocytopenic purpura, expected in H1 2014 * Says if the results are promising, a phase III study is anticipated to commence in 2015

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below